ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SLN vs OPK // 10Y YIELD & FRED MACRO BETA

Silence Therapeutics Plc American Depository Share (NASDAQ) VS. OPKO Health Inc. (NASDAQ) • 15-METRIC TALLY: SLN 4 — OPK 5
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SLN VS. OPK) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SLN OPK SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 61.50% 33.90% +27.60 SLN /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -10.20% -24.80 OPK /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -5.06% -14.41% +9.35 SLN /fcf-yield <GO>
Operating Margin -60.00% -19.30% -40.70 OPK /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -65.00% -14.90% -50.10 OPK /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.36 0.20 +3.16 SLN /balance-sheet <GO>
Piotroski F-Score Quality 3/9 4/9 -1.00 OPK /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 78.9 58.9 +20.05 SLN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.23B $1.24B -$8.3M OPK /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SLN REV OPK REV SLN GROSS % OPK GROSS % SLN FCF OPK FCF
FY 2025 $559.0K $606.9M 61.5% 33.9% -$62.3M -$178.5M
FY 2024 $43.3M $713.1M 72.7% 30.6% -$67.9M -$183.5M
FY 2023 $31.6M $863.5M — — -$49.5M -$28.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SLN // BETA —
OPK // BETA —